Capricor Therapeutics Inc Stock Nasdaq
Equities
US14070B1017
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 21.4M | Sales 2025 * | 89.52M | Capitalization | 162M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 8M | EV / Sales 2024 * | 7.58 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
-5.34
x | P/E ratio 2025 * |
52.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.8% |
Latest transcript on Capricor Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.23% | 22.02B | |
-17.84% | 20.9B | |
-9.42% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |